At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 27 enrolled
Drug / intervention
Fiasp +1 moredrug
Likely dose
Fiasp 670Gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy: To Assess How the 670G System Adapts to the Introduction of Fiasp® Insulin
In Brief
A Phase 4 clinical trial evaluating Fiasp and Novolog for Diabetes Mellitus, Type 1. Completed, enrolled 27 participants across 2 sites.
Detailed Summary
This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how Fiasp® works in a closed-loop system and to determine if any changes need to be made to the 670G pump to optimize the use of Fiasp®.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
CollaboratorsMedtronic
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedJun 13, 2018
Enrollment StartJul 23, 2018
Primary CompletionMar 30, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.1 years ago
Interventions
Fiaspdrug
Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system
Novologdrug
Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system